Vanderbilt Vaccine Center

genetic sequence

Genotyping project to be an ‘engine of discovery’

Vanderbilt University researchers next month will launch a major initiative to acquire “dense genotypes” from 100,000 individuals whose medical histories are known.

Study could lead to vaccine for mosquito-borne dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.

HIV cell

‘Redesigned’ antibodies may control HIV: study

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.

VU lands $9 million NIH grant to design better flu vaccines

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

1 8 9 10 11 12 14